8-K: Y-mAbs Therapeutics Stockholders Approve Key Proposals at Annual Meeting

Y-mAbs Therapeutics, Inc. announced the successful approval of all three proposals, including the election of a Class I director, ratification of its independent auditor, and advisory approval of executive compensation, at its annual meeting of stockholders held on July 11, 2025.

Summary

• Y-mAbs Therapeutics, Inc. held its annual meeting of stockholders on July 11, 2025, with a quorum present.
• Stockholders voted on three key proposals as detailed in the Definitive Proxy Statement on Schedule 14A filed on May 30, 2025.
• David N. Gill was elected as a Class I director, to hold office until the Company's 2028 annual meeting of stockholders.
• The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
• The compensation of the Company's named executive officers was approved in a non-binding advisory vote.

Sentiment

Score: 8

Explanation: All management-backed proposals were approved by stockholders with significant 'For' votes, indicating strong shareholder support for current governance and executive compensation, which is a positive sign for corporate stability.

Positives

• Stockholders elected David N. Gill as a Class I director with 18,926,572 votes For, indicating strong support for the board's composition.
• The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm was ratified with overwhelming support, receiving 32,884,437 votes For.
• The non-binding advisory vote on the compensation of named executive officers passed with 27,011,027 votes For, reflecting shareholder alignment with executive pay practices.

Future Outlook

David N. Gill was elected as a Class I director to serve until the Company's 2028 annual meeting of stockholders, ensuring continuity in board leadership.

Industry Context

This filing represents a routine corporate governance update, common across publicly traded companies, reflecting the outcomes of their annual stockholder meetings. It does not contain information specific to broader industry trends or competitive positioning.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Demonstrated alignment with management and the board by approving all proposals.
• Named Executive Officers: Their compensation plan received advisory approval, indicating shareholder support.
• Auditors: PricewaterhouseCoopers LLP's role as independent auditor was ratified, confirming their continued engagement.

Next Steps

• David N. Gill will serve as a Class I director until the Company's 2028 annual meeting of stockholders.
• PricewaterhouseCoopers LLP will continue as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Y-mAbs Therapeutics, Annual Meeting, Stockholder Vote, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, SEC Filing, Form 8-K, PricewaterhouseCoopers LLP